Skip to main content
Erschienen in: Journal of Nuclear Cardiology 2/2019

01.04.2019 | Editorial

Ischemia and inflammation on chronic kidney disease

verfasst von: Nagara Tamaki, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

Compared with the general population, dialysis patients have a greater incidence of cardiovascular death, mainly due to the high prevalence of either underlying coronary artery disease before starting hemodialysis or cardiovascular risk factors in those with end stage renal disease.14 Chronic kidney disease (CKD) in general, has a higher incidence of coronary artery disease. The adjusted hazard ratio for death and cardiovascular events increases inversely with estimated glomerular filtration rates (eGFR).5,6
Literatur
1.
Zurück zum Zitat Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S16-23.PubMed Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S16-23.PubMed
2.
Zurück zum Zitat Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 2001;12:1516-23.PubMed Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 2001;12:1516-23.PubMed
3.
Zurück zum Zitat Foley RN, Parfrey PS. Cardiac disease in chronic uremia: Clinical outcome and risk factors. Adv Ren Replace Ther 1997;4:234-48.CrossRefPubMed Foley RN, Parfrey PS. Cardiac disease in chronic uremia: Clinical outcome and risk factors. Adv Ren Replace Ther 1997;4:234-48.CrossRefPubMed
4.
Zurück zum Zitat Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002;40:307-14.CrossRefPubMed Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002;40:307-14.CrossRefPubMed
5.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardio vascular events, and hospitalization. N Engl J Med 2004;351:1296-305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardio vascular events, and hospitalization. N Engl J Med 2004;351:1296-305.CrossRefPubMed
6.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular diseases: A statement from the American Heart Association Councils on Kidney in cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular diseases: A statement from the American Heart Association Councils on Kidney in cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.CrossRefPubMed
7.
Zurück zum Zitat Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: A randomized controlled trial. Am J Kidney Dis 2009;54:602-09.CrossRefPubMed Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: A randomized controlled trial. Am J Kidney Dis 2009;54:602-09.CrossRefPubMed
8.
Zurück zum Zitat Hatta T, Nishimura S, Nakajima T. Prognostic risk stratification of myocardial ischaemia evaluated by gated myocardial perfusion SPECT in patients with chronic kidney disease. Eur J Nucl Mol Imaging 2009;36:1835-41.CrossRef Hatta T, Nishimura S, Nakajima T. Prognostic risk stratification of myocardial ischaemia evaluated by gated myocardial perfusion SPECT in patients with chronic kidney disease. Eur J Nucl Mol Imaging 2009;36:1835-41.CrossRef
9.
Zurück zum Zitat Nakajima K, Nishimura T. Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated SPECT with 99mTc-tetrofosmin: A multicentre study involving 106 hospitals. Eur J Nucl Med Mol Imaging 2006;33:127-33.CrossRefPubMed Nakajima K, Nishimura T. Inter-institution preference-based variability of ejection fraction and volumes using quantitative gated SPECT with 99mTc-tetrofosmin: A multicentre study involving 106 hospitals. Eur J Nucl Med Mol Imaging 2006;33:127-33.CrossRefPubMed
10.
Zurück zum Zitat Momose M, Babazono T, Kondo C, Kobayashi H, Nakajima T, Kusakabe K. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. Eur J Nucl Mol Imaging 2009;36:1315-21.CrossRef Momose M, Babazono T, Kondo C, Kobayashi H, Nakajima T, Kusakabe K. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. Eur J Nucl Mol Imaging 2009;36:1315-21.CrossRef
11.
Zurück zum Zitat Hase H, Joki N, Ishikawa H, Fukuda H, Imamura Y, Saijyo T, et al. Prognostic value of stress myocardial perfusion imaging using adenosine triphosphate at the beginning of haemodialysis treatment in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19:1161-67.CrossRefPubMed Hase H, Joki N, Ishikawa H, Fukuda H, Imamura Y, Saijyo T, et al. Prognostic value of stress myocardial perfusion imaging using adenosine triphosphate at the beginning of haemodialysis treatment in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19:1161-67.CrossRefPubMed
12.
Zurück zum Zitat Hakeem A, Bhatti S, Dille KS, Cook JR, Samad Z, Roth-Cline MD, et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 2008;118:2540-49.CrossRefPubMed Hakeem A, Bhatti S, Dille KS, Cook JR, Samad Z, Roth-Cline MD, et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 2008;118:2540-49.CrossRefPubMed
13.
Zurück zum Zitat Nakajima K, Matsuo S, Okuyama C, Hatta T, Tsukamoto K, Nishimura S, et al. Cardiac event risk in Japanese subjects estimated using gated myocardial perfusion imaging, in conjunction with diabetes mellitus and chronic kidney disease. Circ J 2012;76:168-75.CrossRefPubMed Nakajima K, Matsuo S, Okuyama C, Hatta T, Tsukamoto K, Nishimura S, et al. Cardiac event risk in Japanese subjects estimated using gated myocardial perfusion imaging, in conjunction with diabetes mellitus and chronic kidney disease. Circ J 2012;76:168-75.CrossRefPubMed
14.
Zurück zum Zitat Doukky R, Fughhi I, Campagnoli T, Wassouf M, Ali A. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol 2017;24:112-18.CrossRefPubMed Doukky R, Fughhi I, Campagnoli T, Wassouf M, Ali A. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol 2017;24:112-18.CrossRefPubMed
15.
Zurück zum Zitat Bhatti S, Hakeem A, Dhanalakota S, Palani G, Husain Z, Jacobsen G, Ananthasubramaniam K. Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction. Eur Heart J Cardiovasc Imaging 2014;15:933-40.CrossRefPubMed Bhatti S, Hakeem A, Dhanalakota S, Palani G, Husain Z, Jacobsen G, Ananthasubramaniam K. Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction. Eur Heart J Cardiovasc Imaging 2014;15:933-40.CrossRefPubMed
16.
Zurück zum Zitat ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease Circulation 2012;126:e354-e471. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease Circulation 2012;126:e354-e471.
Metadaten
Titel
Ischemia and inflammation on chronic kidney disease
verfasst von
Nagara Tamaki, MD, PhD
Publikationsdatum
01.04.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 2/2019
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-017-0997-6

Weitere Artikel der Ausgabe 2/2019

Journal of Nuclear Cardiology 2/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.